BIOS Health
-56%
est. 2Y upside i
Neural interfaces to understand and use nerve data in medicine.
Rank
#987
Sector
Biotechnology
Est. Liquidity
~5Y
Data Quality
Data: MediumBIOS Health presents a moderate upside opportunity for a job seeker, driven by its innovative AI-powered neural interface technology and strong competitive moat in the high-growth biotechnology sector.
Last updated: March 10, 2026
BIOS Health's AI-powered neural interface platform achieves significant clinical validation and secures major partnerships with pharmaceutical companies, leading to rapid adoption of its neural digital therapies and accelerating AI-driven drug discovery. Revenue scales to over $50M by 2026, justifying a $480M+ valuation at a 120x multiple, driven by strong IP and market leadership in a nascent but rapidly expanding market.
The company continues to make steady progress in R&D and expands its clinical trial partnerships, establishing its platform as a key tool in bioelectronic medicine. Revenue grows to $15M-$20M by 2026, supporting a valuation of $180M, reflecting continued investor confidence in its long-term potential but with slower commercialization than the bull case.
Significant regulatory hurdles or slower-than-expected clinical trial progress delay commercialization. Intense competition from well-funded incumbents like Neuralink or large medical device companies erodes market share, leading to a down round or acquisition at a significantly reduced valuation of $30M, wiping out most common stock value due to liquidation preferences.
Preference Stack Risk
highInvestors hold approximately $26M in liquidation preferences ahead of common stock, representing 21.67% of the estimated $120M current valuation.
Dilution Risk
highAs a Series A company with high capital intensity, BIOS Health will likely require several more significant funding rounds, leading to substantial future dilution for existing equity holders.
Secondary Liquidity
noneGiven its Series A stage, there is currently no active secondary market or tender offers for BIOS Health equity.
Questions to Ask at the Interview
Strategic questions based on BIOS Health's data — designed to show you've done your homework.
- 1
“Given the 'very high' capital intensity and the need for significant R&D, how is BIOS Health planning to manage its burn rate and secure future funding rounds without excessive dilution for early employees?”
- 2
“With Neuralink as a direct competitor and large medical device companies potentially entering the space, what specific strategies is BIOS Health employing to maintain and strengthen its 'strong competitive moat' in the next 2-3 years?”
- 3
“Considering the long regulatory pathways in biotech, what are the key milestones and realistic timelines for your lead neural digital therapies to achieve significant commercialization, and how might this impact employee equity liquidity?”
Community
Valuation Sentiment
Our model estimates -56% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.